Alzohis is a young innovative biotechnology company created in 2014.
Alzohis provides a new molecular diagnostic test for Alzheimer’s disease. A novel combination of biomarkers leading to a typical “signature” detectable in the blood. This signature is able to discriminate patients suffering from Alzheimer’s disease (AD) from healthy ones and from other neurodegenerative diseases. Alzohis, a new tool for physicians. This diagnosis is based among others on the measure of specific blood biomarkers. Today this type of score, based on a computational model, is relatively well accepted by the medical community (business model identical to diagnosis of trisomy 21, hepatitis C ...).
Alzheimer's disease is so common that it is currently an issue of global general interest. It also affects the family of sufferers, putting them under intense psychological, social and financial pressure. We need an earlier diagnosis, in order to provide better care!
Alzohis has expertises in : (i)Biomolecular analysis, (ii) Development of algorithms, (iii) Management of big data in a secure environment.
Alzohis has the ambition to provide a revolutionary diagnostic tools to help neurologists and specialists to secure their diagnosis.
This disease is detected very late, on average 3-4 years after the first symptoms. Alzohis develops the first reliable non-invasive molecular diagnostic method. It's clear now that Alzheimer's begins decades before symptoms start and that the best treatments will likely begin early, before there is too much damage to reverse.
The development of new curative treatments of AD is strongly correlated to the conception of earlier and more specific diagnoses. Biomolecular-based diagnostic methods currently available for Alzheimer’s disease are still insufficient in terms of precocity and performances. This slows the development of new pharmaceutical molecules with curative intent.
SIMPLE : NON-INVASIVE SOLUTIONS
The physician prescribes the Alzohis Test when his patient presents cognitive impairments or clinical symptoms.
As soon as possible, the patient goes to a medical laboratory close to his home for a standard blood test
The analysis is performed by the laboratory. Less than one hour is required.
The laboratory or the physician connects through a secured connection with the Alzohis platform and sends the blood test results.
The Alzohis tests are calculated in our secured environment, using our powerful algorithms.
The result sheet listing all the relevant information is immediately available for the doctor.
Discovered in 1906 by Aloïs Alzheimer, Alzheimer's disease is a brain disorder. It leads to a progressive loss of neurons.
The moment when the diagnosis is made during the patient’s life. Three different diagnoses were considered, represented by a patient P, “early patient” diagnosed at mild stage, a patient M, “average patient” diagnosed at the start of the moderate stage and a patient T, “late patient” diagnosed at the end of the moderate stage.
We provide revolutionary diagnostic tools to help neurologists and specialists to better secure your diagnosis.
Alzheimer's disease is a major medical problem, with a prevalence in the developed countries of more than 1%, which greatly increases with age. It is clear now that alzheimer's disease begins decades before symptoms start and that the best treatments will likely begin early before there is too much damage to reverse. The current diagnostic strategies for Alzheimer's disease are still inadequate in terms of precocity and performances, slowing considerably the development of new pharmaceutical molecules with a curative intent.
The determination of plasma mono-amine levels is of clinical importance in the diagnosis of some tumors of the nervous system. The plasma concentrations of metabolites may then be several times above the upper reference limits. Also for scientific questions in the area of stress research and in sports, medicine mono-amines levels provide useful information. For pharmacological functional tests, it is necessary to measure plasma levels.
The quantitative determination of blood metabolites is not only useful in differential diagnoses of hypertension but also for the evaluation of a number of other clinical and pharmacological aspects. The concentrations of these are indicative for the activity of the sympathetic nervous system, and are important parameters in congestive cardiac insufficiency, coronary heart disease, diabetes mellitus, arteriosclerosis, acute asthma, and others.
Strategies and analytical methods are available for medical laboratories.
Better diagnosis for better treatment : The development of new curative treatments of AD is strongly linked to the conception of earlier and more specific diagnoses. Diagnostic methods currently available for Alzheimer’s disease and based on biochemical analyzes are still insufficient. This slows the development of new pharmaceutical molecules with curative possibilities.
Disruptive innovation in the diagnosis for patient suffuring from neurodegenerative diseases
Neurodegeneration is the umbrella term for the progressive loss of structure or functions of neurons, including the death of neurons. Many neurodegenerative diseases including amyotrophic lateral sclerosis, Parkinson's or Alzheimer's disease, Progressive supranuclear palsy and Frontotemporal lobar degeneration occur as a result of neurodegenerative processes. Such diseases are incurable, resulting in progressive degeneration and/or the death of neuron cells.
A Powerful diagnosis of Alzheimer's disease
Alzohis, simple and non-invasive test to discriminate Alzheimer and other neurodegenerative diseases
Diagnosis available immediatly for the doctor. Online generation / online access.
Founder of Alzohis has pitched at Hôtel de Ville - Paris with Réseau Entreprendre.
At this occasion, the Alzohis team will share news with all committee members, both scientific and strategic in order to define and plan together a road map and share an accurate vision for the project.
An analysis of prevalence, incidence, cost and trends updates ADI's global dementia data. By carrying out a full update of previous systematic reviews, the report makes key recommendations to provide a global framework for action on dementia.
Alzohis team is laureate of the 2015 promotion of Réseau Entreprendre Paris.
There is no treatment currently available to cure dementia or to alter its progressive course. Numerous new treatments are being investigated in various stages of clinical trials. Much can be, however, offered to support and improve the lives of people with dementia and their caregivers and families. The principal goals for dementia care are: (i) early diagnosis (ii) optimizing physical health, cognition, activity and well-being (iii) identifying and treating the accompanying physical illnesses (iv) detecting and treating behavioral and psychological symptoms (v) providing information and long-term support to caregivers.OMS 2015
A:Talk to your doctor. This test is performed only on medical prescription.
A:The test is effective from the first specific symptoms of certain neurodegenerative diseases. To find out, ask your specialist to confirm your cognitive score before performing the Alzohis test.
A:A revolutionary diagnostic tool from a simple blood test to help neurologists and specialists better secure their diagnosis.
A:It is important for us to learn about his disease to slow the appearence of frailty by an appropriate clinical monitoring which is most effective when it begins early.
A:This diagnosis is based on, amongst other factors, the level of neurotransmitters from a simple blood test, read using an algorithm currently under development.
A:You can receive our newsletter automatically by entering your email address on our website. Currently Alzohis completes clinical trials, and this test will be on the market later this year.
« Dementia is caused by a variety of diseases and injuries that primarily or secondarily affect the brain, such as Alzheimer's disease or stroke »
« The Alzheimer’s Association works on a global, national and local level to enhance care and support for all those affected by Alzheimer’s and other dementias. We are here to help »
« Being able to diagnose Alzheimer's disease more easily, earlier, and more accurately could have a marked effect on the design of clinical studies »
« Studies of solanezumab for Alzheimer's disease have shown that there is a 36% rate of false diagnosis of Alzheimer's disease in clinical trials that were made in expert centres but based only on clinical criteria »